Ruby Yun-Ju Huang

List of Publications by Year
in descending order

89 papers	17,498 citations	87843 38 h-index	64755 79 g-index
95 all docs	95 docs citations	95 times ranked	27268 citing authors

#	Article	IF	Citations
1	Epithelial-Mesenchymal Transitions in Development and Disease. Cell, 2009, 139, 871-890.	13.5	8,592
2	EMT: 2016. Cell, 2016, 166, 21-45.	13.5	3,573
3	Epithelialâ€mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Molecular Medicine, 2014, 6, 1279-1293.	3.3	612
4	Dual role of autophagy in hallmarks of cancer. Oncogene, 2018, 37, 1142-1158.	2.6	403
5	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death and Disease, 2013, 4, e915-e915.	2.7	363
6	Early events in cell adhesion and polarity during epithelial-mesenchymal transition. Journal of Cell Science, 2012, 125, 4417-4422.	1.2	286
7	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Molecular Medicine, 2013, 5, 1051-1066.	3.3	235
8	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. European Urology, 2019, 75, 423-432.	0.9	205
9	Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. Nature Cell Biology, 2014, 16, 745-757.	4.6	187
10	Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1191731.	2.1	178
11	Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integrative Biology (United Kingdom), 2013, 5, 381-389.	0.6	150
12	Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. Frontiers in Pharmacology, 2018, 9, 1294.	1.6	141
13	AXL-Driven EMT State as a Targetable Conduit in Cancer. Cancer Research, 2017, 77, 3725-3732.	0.4	136
14	GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Scientific Reports, 2016, 6, 19943.	1.6	119
15	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtypeâ€“specific therapeutic target for ovarian cancer. Science Signaling, 2016, 9, ra97.	1.6	105
16	FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell Death and Disease, 2014, 5, e1346-e1346.	2.7	99
17	A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Letters, 2016, 382, 203-214.	3.2	99
18	Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecologic Oncology, 2004, 94, 197-203.	0.6	97

#	Article	IF	Citations
19	Stopping transformed cancer cell growth by rigidity sensing. Nature Materials, 2020, 19, 239-250.	13.3	81
20	Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-ÂB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis, 2004, 26, 45-52.	1.3	80
21	The <scp>EMT</scp> spectrum and therapeutic opportunities. Molecular Oncology, 2017, 11, 878-891.	2.1	80
22	Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening. Advanced Healthcare Materials, 2014, 3, 609-616.	3.9	77
23	Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers, 2020, 12, 238.	1.7	70
24	Targeting Pathways Contributing to Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian Cancer. Current Drug Targets, 2012, 13, 1649-1653.	1.0	68
25	Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine, 2019, 50, 203-210.	2.7	67
26	CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget, 2015, 6, 43843-43852.	0.8	66
27	â€˜Lncâ€™â€ing Wnt in female reproductive cancers: therapeutic potential of long nonâ€coding RNAs in Wnt signalling. British Journal of Pharmacology, 2017, 174, 4684-4700.	2.7	62
28	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor ÎºB. Oncogene, 2005, 24, 390-398.	2.6	61
29	Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. Biomaterials, 2014, 35, 1562-1571.	5.7	59
30	The role of GRHL2 and epigenetic remodeling in epithelialâ€“mesenchymal plasticity in ovarian cancer cells. Communications Biology, 2019, 2, 272.	2.0	58
31	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Human Pathology, 2015, 46, 1-8.	1.1	55
32	Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. Cancers, 2020, 12, 24.	1.7	53
33	Histotype-specific copy-number alterations in ovarian cancer. BMC Medical Genomics, 2012, 5, 47.	0.7	52
34	Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. Physical Biology, 2019, 16, 041004.	0.8	49
35	Copy Number Variation Analysis of Matched Ovarian Primary Tumors and Peritoneal Metastasis. PLoS ONE, 2011, 6, e28561.	1.1	47
36	Actin cytoskeleton self-organization in single epithelial cells and fibroblasts under isotropic confinement. Journal of Cell Science, 2019, 132, .	1.2	43

#	Article	IF	Citations
37	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
38	Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). Oncotarget, 2015, 6, 22098-22113.	0.8	42
39	Configurable 2D and 3D spheroid tissue cultures on bioengineered surfaces with acquisition of epithelialâ€“mesenchymal transition characteristics. NPG Asia Materials, 2012, 4, e27-e27.	3.8	41
40	RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling. Cancer Research, 2020, 80, 219-233.	0.4	40
41	Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies. Cells Tissues Organs, 2022, 211, 222-237.	1.3	40
42	Target cell movement in tumor and cardiovascular diseases based on the epithelialâ€“mesenchymal transition concept. Advanced Drug Delivery Reviews, 2011, 63, 558-567.	6.6	38
43	Linking Epithelial-Mesenchymal Transition to the Well-Known Polarity Protein Par6. Developmental Cell, 2005, 8, 456-458.	3.1	31
44	SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. Scientific Reports, 2019, 9, 8295.	1.6	31
45	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Reports, 2018, 19, .	2.0	30
46	Hypoxia-inducible factor-1Î± promotes cell survival during ammonia stress response in ovarian cancer stem-like cells. Oncotarget, 2017, 8, 114481-114494.	0.8	28
47	Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120â€catenin. International Journal of Cancer, 2008, 123, 801-809.	2.3	26
48	Functional reservoir microcapsules generated via microfluidic fabrication for long-term cardiovascular therapeutics. Lab on A Chip, 2020, 20, 2756-2764.	3.1	26
49	Intracellular Hyper-Acidification Potentiated by Hydrogen Sulfide Mediates Invasive and Therapy Resistant Cancer Cell Death. Frontiers in Pharmacology, 2017, 8, 763.	1.6	25
50	Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells. Journal of Biological Chemistry, 2020, 295, 6387-6400.	1.6	25
51	Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Ironâ€“Sulfur Cluster Biogenesis Deficit. Antioxidants and Redox Signaling, 2020, 33, 1191-1208.	2.5	25
52	Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. Journal of Translational Medicine, 2012, 10, 121.	1.8	21
53	LNK (SH2B3): paradoxical effects in ovarian cancer. Oncogene, 2015, 34, 1463-1474.	2.6	21
54	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. Gene, 2017, 635, 9-15.	1.0	20

#	Article	IF	Citations
55	Decoding transcriptomic intraâ€tumour heterogeneity to guide personalised medicine in ovarian cancer. Journal of Pathology, 2019, 247, 305-319.	2.1	18
56	A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening. Analyst, The, 2014, 139, 4846-4854.	1.7	17
57	The FZD 7â€•TWIST 1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Molecular Oncology, 2019, 13, 757-780.	2.1	16
58	Spotlight on the Granules (Grainyhead-Like Proteins) â€“ From an Evolutionary Conserved Controller of Epithelial Trait to Pioneering the Chromatin Landscape. Frontiers in Molecular Biosciences, 2020, 7, 213.	1.6	14
59	Putting the BRK on breast cancer: From molecular target to therapeutics. Theranostics, 2021, 11, 1115-1128.	4.6	14
60	High-throughput functional profiling of single adherent cells via hydrogel drop-screen. Lab on A Chip, 2021, 21, 764-774.	3.1	13
61	SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. Cancers, 2020, 12, 1140.	1.7	10
62	3D genome organization in the epithelial-mesenchymal transition spectrum. Genome Biology, 2022, 23, .	3.8	10
63	Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells. Cell Biology International, 2012, 36, 833-841.	1.4	9
64	Targeting the AXL signaling pathway in ovarian cancer. Molecular and Cellular Oncology, 2017, 4, e1263716.	0.3	9
65	Prognostic significance of phosphoglycerate dehydrogenase in breast cancer. Breast Cancer Research and Treatment, 2021, 186, 655-665.	1.1	9
66	A reasoned approach towards administering COVIDâ€19 vaccines to pregnant women. Prenatal Diagnosis, 2021, 41, 1018-1035.	1.1	9
67	Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. Frontiers in Oncology, 2021, 11, 783803.	1.3	9
68	Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior. ACS Pharmacology and Translational Science, 2020, 3, 1083-1099.	2.5	8
69	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. Npj Breast Cancer, 2021, 7, 88.	2.3	8
70	Clinical Presentation of Pelvic Tuberculosis Imitating Ovarian Malignancy. Taiwanese Journal of Obstetrics and Gynecology, 2004, 43, 29-34.	0.5	7
71	Epigenetic derepression converts PPARÎ³ into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discovery, 2021, 7, 265.	2.0	7
72	A new dimension in drug discovery: reversing epithelialâ€“mesenchymal transition (EMT). Cell Death and Disease, 2016, 7, e2417-e2417.	2.7	4

#	Article	IF	Citations
73	Reply to Pontus Eriksson and Gottfrid SjÃ¶dahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423â€“32. European Urology, 2019, 75, e108-e109.	0.9	4
74	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Scientific Reports, 2020, 10, 18503.	1.6	4
75	Two high-yield complementary methods to sort cell populations by their 2D or 3D migration speed. Molecular Biology of the Cell, 2020, 31, 2779-2790.	0.9	1
76	Case study: Digital spatial profiling of metastatic clear cell carcinoma reveals intra-tumor heterogeneity in epithelial-mesenchymal gradient. , 0, , .		1
77	Evolution of CP2 transcription factors in Hexapoda. Journal of Genetics, 2021, 100, 1.	0.4	1
78	Drug Screening: Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening (Adv. Healthcare Mater. 4/2014). Advanced Healthcare Materials, 2014, 3, 620-620.	3.9	0
79	Abstract 1058: Grainyhead-like 2 regulates molecular subtype switching in epithelial ovarian cancer. , 2014, , .		0
80	Abstract POSTER-TECH-1112: Quantitate epithelial-mesenchymal transition in ovarian cancer. , 2015, , .		0
81	Abstract POSTER-BIOL-1301: The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer. , 2015, , .		0
82	Abstract POSTER-THER-1403: FZD7 drives aggressiveness in stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. , 2015, , .		0
83	Abstract 1430: Transcriptional regulatory loops among SNAI1, TWIST1, ZEB1, and ZEB2 defines the epithelial-mesenchymal transition (EMT) spectrum in epithelial ovarian cancer (EOC). , 2015, , .		0
84	Abstract A30: Frizzled-7 (FZD7)-mediated non-canonical Wnt-Planar Cell Polarity (PCP) signalling pathway as a novel molecular driver for the C5/Proliferative/Stem-A molecular subtype of ovarian cancer.. , 2016, , .		0
85	Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.. Journal of Clinical Oncology, 2016, 34, e17084-e17084.	0.8	0
86	Abstract 4490: Comparisons of genetic alterations of breast cancer between East and West: Special emphases on young patients with ER+/HER2- tumors. , 2016, , .		0
87	KDM4B under hypoxia: a new targetable pathway for epithelial ovarian cancer?. Translational Cancer Research, 2017, 6, S93-S95.	0.4	0
88	Abstract 1820: Synergistic lethality of mAbs with an EMT reversal agent, Nintedanib, in epithelial ovarian cancer. , 2017, , .		0
89	Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.. Journal of Clinical Oncology, 2020, 38, e15640-e15640.	0.8	0